<?xml encoding="utf-8" ?> AVITA Medical RCEL reported third-quarter financial results on Thursday. The transcript from the ...
Tech Times on MSN
Oral drug MB-388 enters human testing, targeting cancer's immune silencing that defeats checkpoint therapy
Mondego Bio doses first humans with oral MB-388, an immunotherapy-resistance drug targeting the PTPN2/PTPN1 pathway. Phase 1a ...
Zai Lab's China business stabilizes as its lead cancer drug nears a 2027 filing. Founder, Chairperson, and Chief Executive ...
A comprehensive review finds that Traditional Chinese Medicine formulas and compounds modulate multiple pathological ...
Operator: Hello, and welcome to Vir Biotechnology's Third Quarter 2026 Financial Results and Corporate Update Conference Call ...
As I browse my social media timelines and online news, I have been seeing headlines like these more and more often. "Revealed ...
Updated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in ...
SE: AI is disruptive to EDA, the semiconductor industry, and to their customers. One early indication is that computer ...
Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary ...
One hinted that a little AI-powered math practice might help struggling middle schoolers improve their skills. The other ...
Aura Biosciences offers a fully funded ocular oncology play with a Phase 3 upside and limited financing risk. Click to read ...
InnoCare’s orelabrutinib posts 32.8% durable platelet response in Phase III ITP, topping Sanofi’s rilzabrutinib. NMPA NDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results